Market research
RPGLIFE.NSE RPG Life Sciences Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 45B
- P/E ratio
- 37.3
- Analyst target
- 3205
- Dividend yield
- 0.0%
- Beta
- -0.22
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE105J01010
- Market cap
- 45B
- P/E ratio
- 37.3
- Analyst target
- 3205
- Dividend yield
- 0.0%
- Beta
- -0.22
About
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RPGLIFE.NSE discussion.
5 years, 5 months ago
RPG Life Sciences Limited is currently in a long term uptrend where the price is trading 10.3% above its 200 day moving average.
From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
RPG Life Sciences Limited's total revenue rose by 14.0% to $1B since the same quarter in the previous year.
Its net income has increased by 62.7% to $129M since the same quarter in the previous year.
Finally, its free cash flow fell by 52.8% to $166M since the same quarter in the previous year.
Based on the above factors, RPG Life Sciences Limited gets an overall score of 4/5.